IDEAYA Biosciences reports Q3 cash and securities of $1.14 billion

Reuters

2025/11/04

<a href="https://laohu8.com/S/IDYA">IDEAYA Biosciences</a> reports Q3 cash and securities of $1.14 billion

IDEAYA Biosciences Inc. reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2025, up from $991.9 million on June 30, 2025. The increase was primarily due to a $210 million upfront payment from Servier under an exclusive license agreement for darovasertib outside the United States. For the third quarter ended September 30, 2025, collaboration revenue totaled $207.8 million, compared to zero in the previous quarter. Under the Servier agreement, IDEAYA is eligible for up to $100 million in regulatory milestone payments, up to $220 million in commercial milestone payments, and double-digit royalties on net sales outside the United States. IDEAYA retains all rights to darovasertib in the United States and will share development costs with Servier. As of September 30, 2025, $143.1 million in research and development service obligations remain to be recognized as collaboration revenue. The company expects its current funds to support operations into 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF14392) on November 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580827957"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580827957\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580827957?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580827957","market":"nz","top_or_hot":-1,"title":"IDEAYA Biosciences reports Q3 cash and securities of $1.14 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> reports Q3 cash and securities of $1.14 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEAYA Biosciences Inc. reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2025, up from $991.9 million on June 30, 2025. The increase was primarily due to a $210 million upfront payment from Servier under an exclusive license agreement for darovasertib outside the United States. For the third quarter ended September 30, 2025, collaboration revenue totaled $207.8 million, compared to zero in the previous quarter. Under the Servier agreement, IDEAYA is eligible for up to $100 million in regulatory milestone payments, up to $220 million in commercial milestone payments, and double-digit royalties on net sales outside the United States. IDEAYA retains all rights to darovasertib in the United States and will share development costs with Servier. As of September 30, 2025, $143.1 million in research and development service obligations remain to be recognized as collaboration revenue. The company expects its current funds to support operations into 2030.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF14392) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA Biosciences reports Q3 cash and securities of $1.14 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA Biosciences reports Q3 cash and securities of $1.14 billion\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-04 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> reports Q3 cash and securities of $1.14 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEAYA Biosciences Inc. reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2025, up from $991.9 million on June 30, 2025. The increase was primarily due to a $210 million upfront payment from Servier under an exclusive license agreement for darovasertib outside the United States. For the third quarter ended September 30, 2025, collaboration revenue totaled $207.8 million, compared to zero in the previous quarter. Under the Servier agreement, IDEAYA is eligible for up to $100 million in regulatory milestone payments, up to $220 million in commercial milestone payments, and double-digit royalties on net sales outside the United States. IDEAYA retains all rights to darovasertib in the United States and will share development costs with Servier. As of September 30, 2025, $143.1 million in research and development service obligations remain to be recognized as collaboration revenue. The company expects its current funds to support operations into 2030.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF14392) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL91kl9M:1","article_id":"2580827957","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580827957","pubTimestamp":1762254092,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IDEAYA Biosciences Inc. reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2025, up from $991.9 million on June 30, 2025. The increase was primarily due to a $210 million upfront payment from Servier under an exclusive license agreement for darovasertib outside the United States. For the third quarter ended September 30, 2025, collaboration revenue totaled $207.8 million, compared to zero in the previous quarter. Under the Servier agreement, IDEAYA is eligible for up to $100 million in regulatory milestone payments, up to $220 million in commercial milestone payments, and double-digit royalties on net sales outside the United States. IDEAYA retains all rights to darovasertib in the United States and will share development costs with Servier. As of September 30, 2025, $143.1 million in research and development service obligations remain to be recognized as collaboration revenue. The company expects its current funds to support op","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences","BK4139":"生物科技"},"translate_title":"IDEAYA Biosciences报告第三季度现金和证券为11.4亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":0.9},"content_text":"IDEAYA Biosciences reports Q3 cash and securities of $1.14 billion\n    \n\n        IDEAYA Biosciences Inc. reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2025, up from $991.9 million on June 30, 2025. The increase was primarily due to a $210 million upfront payment from Servier under an exclusive license agreement for darovasertib outside the United States. For the third quarter ended September 30, 2025, collaboration revenue totaled $207.8 million, compared to zero in the previous quarter. Under the Servier agreement, IDEAYA is eligible for up to $100 million in regulatory milestone payments, up to $220 million in commercial milestone payments, and double-digit royalties on net sales outside the United States. IDEAYA retains all rights to darovasertib in the United States and will share development costs with Servier. As of September 30, 2025, $143.1 million in research and development service obligations remain to be recognized as collaboration revenue. The company expects its current funds to support operations into 2030.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF14392) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}